RxDoctor Payments Data

Daniel Kelly, MD

Cardiovascular Disease · Jackson, MSNPI 1417480831

Payments from drug & device makers

$2,807in general payments, 2019–2025

Across 103 payments — averaging $27.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$378
  • Novartis$269
  • AstraZeneca$248
  • Merck$192
  • Amgen$190
  • Novo Nordisk$127
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,807 in reported general payments places this provider in the 40th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$249,267
Medicare patients
2,200
Services billed
5,215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$175,788
EntrestoSacubitril/Valsartan169$165,261
XareltoRivaroxaban114$96,136
JardianceEmpagliflozin94$73,619
FarxigaDapagliflozin Propanediol70$66,879
Repatha SureclickEvolocumab34$43,871
Metoprolol Succinate353$4,294
Ezetimibe103$4,186
Rosuvastatin Calcium223$2,172
Atorvastatin Calcium241$1,926
Valsartan103$1,893
Ranolazine ErRanolazine33$1,886
Propafenone Hcl28$1,548
Spironolactone223$1,434
Olmesartan Medoxomil118$1,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$269$165,261169 claims
Johnson & JohnsonXarelto$50$96,136114 claims
Boehringer IngelheimJardiance$378$73,61994 claims
AstraZenecaFarxiga$248$66,87970 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →